BioInvent's BI-1808, Keytruda Show 24% Response Rate in Platinum-Resistant Ovarian Cancer

Bitget2026/10/24 07:23

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BioInvent reported a 24% objective response rate among 34 evaluable patients receiving BI-1808 with Keytruda for heavily pretreated platinum-resistant ovarian cancer.
Disease control reached 53%, with median follow-up of 11.6 months.
Median progression-free survival was 4.1 months versus 2.1 months for pembrolizumab alone in an indirect comparison.
Treatment-related discontinuations occurred in fewer than 5% of 81 solid-tumor patients receiving the combination.
Randomized Part C will test BI-1808 with pembrolizumab and paclitaxel, with optional bevacizumab, starting Q1 2027; initial data are expected H2 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioInvent International AB published the original content used to generate this news brief on October 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BioInvent's BI-1808, Keytruda Show 24% Response Rate in Platinum-Resistant Ovarian Cancer

You may also like

Crypto prices